...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >LAG-3, TGF-{beta}, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L.
【24h】

LAG-3, TGF-{beta}, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L.

机译:LAG-3,TGF-β和细胞内源性PD-1抑制途径有助于同种异体BMT用抗CD40L诱导的CD8,而不是CD4 T细胞耐受性。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Administration of a single dose of anti-CD40L mAb at the time of allogeneic BM transplantation tolerizes peripheral alloreactive T cells and permits establishment of mixed hematopoietic chimerism in mice. Once engrafted, mixed chimeras are systemically tolerant to donor Ags through a central deletion mechanism and will accept any donor organ indefinitely. We previously found that the PD-1/PD-L1 pathway is required for CD8 T-cell tolerance in this model. However, the cell population that must express PD-1 and the role of other inhibitory molecules were unknown. Here, we report that LAG-3 is required for long-term peripheral CD8 but not CD4 T-cell tolerance and that this requirement is CD8 cell-extrinsic. In contrast, adoptive transfer studies revealed a CD8 T cell-intrinsic requirement for CTLA4/B7.1/B7.2 and for PD-1 for CD8 T-cell tolerance induction. We also observed that both PD-L1 and PD-L2 are independently required on donor cells to achieve T-cell tolerance. Finally, we uncovered a requirement for TGF-beta signaling into T cells to achieve peripheral CD8 but not CD4 T-cell tolerance in this in vivo system.
机译:同种异体BM移植时单剂量抗CD40L mAb的给药可耐受外周同种异体反应性T细胞,并允许在小鼠中建立混合的造血嵌合体。一旦植入,混合嵌合体通过中央缺失机制对供体Ag具有系统耐受性,并将无限期接受任何供体器官。我们先前发现在该模型中,PD-1 / PD-L1通路是CD8 T细胞耐受性所必需的。但是,尚不知道必须表达PD-1的细胞群和其他抑制性分子的作用。在这里,我们报告LAG-3是长期外周CD8所必需的,而不是CD4 T细胞耐受性,并且该要求是CD8细胞外源性的。相反,过继转移研究表明,CTLA4 / B7.1 / B7.2和PD-1的CD8 T细胞本征要求诱导CD8 T细胞耐受。我们还观察到,PD-L1和PD-L2都是供体细胞独立获得T细胞耐受性所需的。最后,我们发现在此体内系统中,TGF-β信号转入T细胞以实现外周CD8而不是CD4 T细胞耐受性的要求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号